384 related articles for article (PubMed ID: 23319019)
1. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.
Cronstein BN; Sunkureddi P
J Clin Rheumatol; 2013 Jan; 19(1):19-29. PubMed ID: 23319019
[TBL] [Abstract][Full Text] [Related]
2. Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence.
Bardin T
Joint Bone Spine; 2015 Oct; 82 Suppl 1():eS9-16. PubMed ID: 26717801
[TBL] [Abstract][Full Text] [Related]
3. Doliroside A attenuates monosodium urate crystals-induced inflammation by targeting NLRP3 inflammasome.
Wei H; Hu C; Xie J; Yang C; Zhao Y; Guo Y; Mei Z; Chen L; Lan Z
Eur J Pharmacol; 2014 Oct; 740():321-8. PubMed ID: 25064339
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy.
Schlesinger N
Semin Arthritis Rheum; 2012 Oct; 42(2):155-65. PubMed ID: 22542277
[TBL] [Abstract][Full Text] [Related]
5. Management of acute and chronic gouty arthritis: present state-of-the-art.
Schlesinger N
Drugs; 2004; 64(21):2399-416. PubMed ID: 15481999
[TBL] [Abstract][Full Text] [Related]
6. Gouty arthritis: understanding the disease state and management options in primary care.
Sunkureddi P
Adv Ther; 2011 Sep; 28(9):748-60. PubMed ID: 21894471
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute gouty arthritis: one physician's approach and where this management stands relative to developments in the field.
Wortmann RL
Curr Rheumatol Rep; 2004 Jun; 6(3):235-9. PubMed ID: 15134604
[TBL] [Abstract][Full Text] [Related]
8. Curcumin ameliorates monosodium urate-induced gouty arthritis through Nod-like receptor 3 inflammasome mediation via inhibiting nuclear factor-kappa B signaling.
Li X; Xu DQ; Sun DY; Zhang T; He X; Xiao DM
J Cell Biochem; 2019 Apr; 120(4):6718-6728. PubMed ID: 30592318
[TBL] [Abstract][Full Text] [Related]
9. The inflammatory process of gout and its treatment.
Cronstein BN; Terkeltaub R
Arthritis Res Ther; 2006; 8 Suppl 1(Suppl 1):S3. PubMed ID: 16820042
[TBL] [Abstract][Full Text] [Related]
10. Current concepts in the treatment of gouty arthritis.
Fang ZH; Waizy H
Orthop Surg; 2013 Feb; 5(1):6-12. PubMed ID: 23420740
[TBL] [Abstract][Full Text] [Related]
11. Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra.
Joosten LA; Crişan TO; Azam T; Cleophas MC; Koenders MI; van de Veerdonk FL; Netea MG; Kim S; Dinarello CA
Ann Rheum Dis; 2016 Jun; 75(6):1219-27. PubMed ID: 26174021
[TBL] [Abstract][Full Text] [Related]
12. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis.
Joosten LA; Netea MG; Mylona E; Koenders MI; Malireddi RK; Oosting M; Stienstra R; van de Veerdonk FL; Stalenhoef AF; Giamarellos-Bourboulis EJ; Kanneganti TD; van der Meer JW
Arthritis Rheum; 2010 Nov; 62(11):3237-48. PubMed ID: 20662061
[TBL] [Abstract][Full Text] [Related]
13. Difficult-to-treat gouty arthritis: a disease warranting better management.
Schlesinger N
Drugs; 2011 Jul; 71(11):1413-39. PubMed ID: 21812506
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors.
Wechalekar MD; Vinik O; Moi JH; Sivera F; van Echteld IA; van Durme C; Falzon L; Bombardier C; Carmona L; Aletaha D; Landewé RB; van der Heijde DM; Buchbinder R
J Rheumatol Suppl; 2014 Sep; 92():15-25. PubMed ID: 25180124
[TBL] [Abstract][Full Text] [Related]
15. Management of gouty arthritis in patients with chronic kidney disease.
Abdellatif AA; Elkhalili N
Am J Ther; 2014; 21(6):523-34. PubMed ID: 22960848
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute gout: a systematic review.
Khanna PP; Gladue HS; Singh MK; FitzGerald JD; Bae S; Prakash S; Kaldas M; Gogia M; Berrocal V; Townsend W; Terkeltaub R; Khanna D
Semin Arthritis Rheum; 2014 Aug; 44(1):31-8. PubMed ID: 24650777
[TBL] [Abstract][Full Text] [Related]
17. The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis.
Bardin T; van de Laar MA
Joint Bone Spine; 2015 Oct; 82 Suppl 1():eS30-2. PubMed ID: 26717800
[TBL] [Abstract][Full Text] [Related]
18. Rhein, An Anthraquinone Drug, Suppresses the NLRP3 Inflammasome and Macrophage Activation in Urate Crystal-Induced Gouty Inflammation.
Chang WC; Chu MT; Hsu CY; Wu YJ; Lee JY; Chen TJ; Chung WH; Chen DY; Hung SI
Am J Chin Med; 2019; 47(1):135-151. PubMed ID: 30612459
[TBL] [Abstract][Full Text] [Related]
19. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.
Schlesinger N; Alten RE; Bardin T; Schumacher HR; Bloch M; Gimona A; Krammer G; Murphy V; Richard D; So AK
Ann Rheum Dis; 2012 Nov; 71(11):1839-48. PubMed ID: 22586173
[TBL] [Abstract][Full Text] [Related]
20. Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases.
Avram A; Duarte C; Santos MJ; Papagoras C; Ritis K; Scarpioni R; Schmidt WA; Skendros P
Joint Bone Spine; 2015 Oct; 82 Suppl 1():eS17-29. PubMed ID: 26717798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
